Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2018

At a glance

  • Drugs Gosuranemab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms TANGO
  • Sponsors Biogen
  • Most Recent Events

    • 09 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 22 Jan 2018 Planned End Date changed from 18 Sep 2020 to 8 Sep 2021.
    • 22 Jan 2018 Planned primary completion date changed from 18 Sep 2020 to 21 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top